Increased survival in men with metastatic prostate cancer who receive Docetaxel when starting hormone therapy
According to early results from a randomized controlled clinical trial, men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug Docetaxel ( Taxotere ) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone.
The independent Data and Safety Monitoring Committee overseeing the trial recommended to the National Cancer Institute ( NCI ), part of NIH ( national Institutes of Health ), that the study results be made public because a recent planned interim analysis showed prolongation in overall survival.
The study enrolled 790 men with metastatic prostate cancer between July 2006 and November 2012 in a trial known as E3805. All patients started treatment by receiving a form of hormone therapy known as ADT ( androgen deprivation therapy ).
Androgens regulate male sex characteristics and can stimulate prostate cancer cells.
Men received either ADT alone or ADT with the chemotherapy drug Docetaxel every three weeks over a period of 18 weeks.
In addition to examining whether the study participants lived longer with the addition of chemotherapy, researchers looked at whether the extent of a patient’s metastatic disease was high or low at the start of treatment.
Approximately two-thirds of patients had a high extent of disease which meant the disease had spread to major organs such as the liver, had a spread resulting in four or more bone lesions, or both.
A significant improvement in the overall survival was noted favoring the participants who had received Docetaxel chemotherapy in addition to the ADT compared to the ADT alone ( three-year survival rates of 69.0% vs 52.5% respectively ).
Further analysis showed that patients with a high extent of metastatic disease accounted for most of the benefit in the overall survival from Docetaxel plus ADT ( three-year survival rates of 63.4% vs 43.9% for ADT alone ).
Median follow-up to date is two years.
Since Docetaxel has been shown in previous clinical trials to be beneficial in ADT-resistant disease and is approved by the FDA ( Food and Drug Administration ) for treatment of late-stage prostate cancer, it is available for use now. However, because it is a chemotherapy drug associated with some toxicities, its use in combination with ADT at this time should be restricted to patients with high-extent metastatic prostate cancer who are candidates for treatment with Docetaxel.
This is the group of patients who experienced the most benefit in the current analysis.
Further follow-up will be performed on patients with less extensive metastatic disease who participated in E3805 in order to define the effect of this treatment combination on these patients.
According to Christopher Sweeney, Dana Farber Cancer Institute, Boston, the results of this study are practice-changing. There is strong scientific evidence that patients with the most advanced metastatic prostate cancer benefit from the early addition of Docetaxel to ADT and not waiting until the cancer has progressed on hormonal therapy.
It is estimated that over 238,000 men will be diagnosed with prostate cancer in the United States in 2013 and over 29,000 men will die of the disease. ( Xagena )
Source: National Cancer Institute, 2013
Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...
Apalutamide vs placebo in patients with non-metastatic castration-resistant prostate cancer receiving androgen deprivation therapy: health-related quality of life at final analysis of the SPARTAN study
The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...
European Union: Lynparza approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer: final survival results from SPARTAN, a phase III trial
SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...
Darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer: overall survival results of phase III ARAMIS study
Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...
IPATential150 study: Ipatasertib in combination with Abiraterone and Prednisone / Prednisolone met its co-primary endpoint of radiographic progression free survival in patients with PTEN loss tumours
Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...
Erleada for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease, European Commission approved
The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...
Apalutamide improves overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer
Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...
For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...